132 results
8-K
EX-99.1
SVRA
Savara Inc
2 Aug 07
Adventrx Pharmaceuticals Reports Second Quarter 2007 Financial Results
12:00am
of a clinical study of ANX-201.”
Research and development, or R&D, expenses increased by $1.0 million, or 31%, to $4.2 million for the three-month … period ended June 30, 2007 from $3.2 million for the same period a year ago. The increase in R&D expenses was primarily due to a $485,000 increase
424B3
SVRA
Savara Inc
3 May 10
Prospectus supplement
12:00am
to research and development, or R&D, or to acquisition of our product candidates. We have not yet marketed or sold any products or generated any significant … with the terms of the applicable license agreements.
R&D Expenses. R&D expenses consist of expenses incurred in performing R&D activities, including
8-K
EX-99.1
n0g3jryl9
10 Nov 09
Adventrx Pharmaceuticals Reports Third Quarter Financial Results
12:00am
CORRESP
lij2 841bpcvzg8x
11 Jun 07
Correspondence with SEC
12:00am
424B3
mmit3qn6
10 Aug 10
Prospectus supplement
12:00am
424B3
igeprczsf2rs90 1d
4 Nov 13
Prospectus supplement
12:00am
8-K
EX-99.1
0ox4pll 26mak5j
7 Nov 07
Adventrx Pharmaceuticals Reports Third Quarter 2007 Financial Results
12:00am